IS7637A - Samsetning sem samanstendur af kólestról upptöku hindra, HMG-COA redúktasa hindra og bindiefni - Google Patents

Samsetning sem samanstendur af kólestról upptöku hindra, HMG-COA redúktasa hindra og bindiefni

Info

Publication number
IS7637A
IS7637A IS7637A IS7637A IS7637A IS 7637 A IS7637 A IS 7637A IS 7637 A IS7637 A IS 7637A IS 7637 A IS7637 A IS 7637A IS 7637 A IS7637 A IS 7637A
Authority
IS
Iceland
Prior art keywords
inhibitor
hmg
binder
composition
coa reductase
Prior art date
Application number
IS7637A
Other languages
English (en)
Inventor
D. Moore William
Fitzpatrick Shaun
Seiler Christian
Saklatvala Robert
R. Petts Catherine
Philip Cho Wing-Kee
Original Assignee
Merck Sharp & Dohme Limited
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Limited, Schering Corporation filed Critical Merck Sharp & Dohme Limited
Publication of IS7637A publication Critical patent/IS7637A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IS7637A 2002-07-26 2005-01-10 Samsetning sem samanstendur af kólestról upptöku hindra, HMG-COA redúktasa hindra og bindiefni IS7637A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39869102P 2002-07-26 2002-07-26
PCT/US2003/022889 WO2004010993A1 (en) 2002-07-26 2003-07-22 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent

Publications (1)

Publication Number Publication Date
IS7637A true IS7637A (is) 2005-01-10

Family

ID=31188454

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7637A IS7637A (is) 2002-07-26 2005-01-10 Samsetning sem samanstendur af kólestról upptöku hindra, HMG-COA redúktasa hindra og bindiefni

Country Status (39)

Country Link
US (4) US7229982B2 (is)
EP (2) EP1992343A1 (is)
JP (2) JP2005538104A (is)
KR (2) KR20080070089A (is)
CN (2) CN101069684A (is)
AR (2) AR040588A1 (is)
AT (1) ATE393628T1 (is)
AU (2) AU2003261217B2 (is)
BR (1) BR0312933A (is)
CA (1) CA2493076A1 (is)
CR (1) CR9767A (is)
DE (1) DE60320652T2 (is)
DK (1) DK1531805T3 (is)
EA (1) EA008888B1 (is)
EC (2) ECSP055573A (is)
ES (1) ES2303603T3 (is)
GE (1) GEP20084443B (is)
GT (2) GT200300149A (is)
HK (1) HK1080384A1 (is)
HR (2) HRP20050081A2 (is)
IL (2) IL166279A0 (is)
IS (1) IS7637A (is)
MA (1) MA27289A1 (is)
ME (3) ME00008B (is)
MX (1) MXPA05001004A (is)
MY (1) MY148689A (is)
NO (2) NO20051033L (is)
NZ (1) NZ537611A (is)
PA (1) PA8577901A1 (is)
PE (1) PE20050128A1 (is)
PL (1) PL375065A1 (is)
PT (1) PT1531805E (is)
RS (2) RS20080072A (is)
SI (1) SI1531805T1 (is)
TN (1) TNSN05022A1 (is)
TW (2) TW200412944A (is)
UA (1) UA82489C2 (is)
WO (1) WO2004010993A1 (is)
ZA (1) ZA200500196B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
DE602004029715D1 (de) 2003-12-23 2010-12-02 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
US20070275075A1 (en) * 2006-03-06 2007-11-29 Ilan Zalit Ezetimibe compositions
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
ES2622576T3 (es) 2006-06-19 2017-07-06 Alpharma Pharmaceuticals Llc Composiciones farmacéuticas
CN1994296B (zh) * 2006-08-02 2010-06-16 浙江京新药业股份有限公司 一种含有辛伐他汀的药物制剂
GB0713707D0 (en) 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CN101938995A (zh) * 2007-12-17 2011-01-05 克卡制药新梅斯托股份公司 包含非微粉化依泽替米贝微粒的悬浮液
US20090233898A1 (en) * 2008-03-11 2009-09-17 Glenmark Generics Ltd Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
WO2010066687A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Stabalized statin-comprising compositions
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011002424A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
KR101302243B1 (ko) * 2010-07-28 2013-09-02 씨제이제일제당 (주) 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
CN101978953A (zh) * 2010-10-11 2011-02-23 上海交通大学 基于易吸湿性辅料的固体制剂
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
KR20160031038A (ko) 2011-02-02 2016-03-21 알파마 파머슈티컬스 엘엘씨 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
WO2013034436A1 (de) * 2011-09-08 2013-03-14 Hexal Ag Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
PL2844233T3 (pl) * 2012-05-01 2020-09-07 Althera Life Sciences, Llc Preparat w postaci tabletki do stosowania doustnego składający się ze stałego połączenia rosuwastatyny i ezetymibu w leczeniu hiperlipidemii i chorób sercowo-naczyniowych
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
CN103585146B (zh) * 2013-11-09 2015-04-01 北京中申专利科技有限公司 辛伐他汀的药物组合物
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
CN104306348B (zh) * 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN108348491A (zh) * 2015-11-06 2018-07-31 燿石治疗公司 治疗混合性血脂异常
CN106937952A (zh) * 2016-01-04 2017-07-11 重庆华邦制药有限公司 依折麦布和辛伐他汀的制剂
EP3281649A1 (en) * 2016-08-09 2018-02-14 Teleflex Lifesciences Wetting agent formulation
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2019101150A1 (zh) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 一种海泽麦布片剂及其制备方法
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
WO1988005296A2 (en) 1987-01-27 1988-07-28 Warner-Lambert Company Lpid regulating compositions
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MY131273A (en) 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
KR100281609B1 (ko) * 1991-12-27 2001-02-15 폴락 돈나 엘. 유효 제제를 포함하는 분산액의 동일 반응계내 생성 및 방출을 조절하는 약물 전달 장치
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
JPH06247854A (ja) * 1993-02-24 1994-09-06 Ss Pharmaceut Co Ltd アスコルビン酸含有組成物
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US6369103B1 (en) 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
CA2191455A1 (en) * 1994-06-20 1995-12-28 Wayne Vaccaro Substituted azetidinone compounds useful as hypocholesterolemic agents
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
EP0782451A1 (en) 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DE69621952T2 (de) * 1995-10-31 2003-01-16 Schering Corp Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
CA2251972A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6673831B1 (en) * 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
AU4326197A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Pharmaceutical compositions
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5952003A (en) 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US6251852B1 (en) 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
AU4699099A (en) 1998-06-24 2000-01-10 Merck & Co., Inc. Compositions and methods for treating elevated blood cholesterol
JP2002518448A (ja) 1998-06-24 2002-06-25 メルク エンド カムパニー インコーポレーテッド 高血中コレステロールを治療する組成物および方法
US6099865A (en) 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
JP2000109882A (ja) * 1998-10-01 2000-04-18 Nof Corp 油性粉末、製造方法および用途
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
AU764048B2 (en) 1999-03-08 2003-08-07 Merck & Co., Inc. Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
JP2002538202A (ja) 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
JP2002538189A (ja) 1999-03-10 2002-11-12 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターの投与方法と組成物
JP2000302672A (ja) * 1999-04-16 2000-10-31 Taisho Pharmaceut Co Ltd 咀嚼可能な被覆錠剤
JP3732039B2 (ja) * 1999-05-21 2006-01-05 三菱化学フーズ株式会社 錠剤用組成物
DZ3179A1 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques à base de beta-carboline.
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
WO2001041770A2 (en) 1999-12-08 2001-06-14 Pharmacia Corporation Nanoparticulate eplerenone compositions
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
DK1267880T4 (da) 2000-02-29 2010-05-17 Bristol Myers Squibb Co Entecavir-formulering med lav dosis og anvendelse deraf
JP2004508347A (ja) * 2000-09-06 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シンバスタチンのジヒドロキシ開環酸塩
SI1593670T1 (sl) * 2000-12-20 2007-12-31 Schering Corp S hidroksi substituirani 2-azetidinoni, uporabni kot sredstva za zniĹľevanje holesterola
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
MXPA03005923A (es) * 2000-12-28 2004-01-26 Kissei Pharmaceuticals Co Ltd Derivados de glupopiranosiloxipirazol y su uso en medicinas.
ES2287250T3 (es) 2001-01-26 2007-12-16 Schering Corporation Combinaciones de secuestrante(s) de acidos biliares e inhibidor(es) de la absorcion de esteroles y tratamientos para indicaciones vasculares.
JP2004517920A (ja) 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
PL205343B1 (pl) 2001-01-26 2010-04-30 Schering Corp Zastosowanie inhibitora wchłaniania sterolu
SI1353696T1 (sl) 2001-01-26 2007-04-30 Schering Corp Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
CZ20032031A3 (cs) 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
ES2245733T3 (es) 2001-03-28 2006-01-16 Schering Corporation Sintesis enantioselectiva de compuestos intermedios de azetidinona.
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

Also Published As

Publication number Publication date
TW200412944A (en) 2004-08-01
GT200300149A (es) 2004-03-04
MEP4708A (xx) 2010-02-10
WO2004010993A1 (en) 2004-02-05
NO20051033L (no) 2005-04-25
MY148689A (en) 2013-05-31
DE60320652T2 (de) 2009-06-10
DK1531805T3 (da) 2008-07-07
US7718643B2 (en) 2010-05-18
CN1671376A (zh) 2005-09-21
DE60320652D1 (de) 2008-06-12
TW200906388A (en) 2009-02-16
CA2493076A1 (en) 2004-02-05
US7229982B2 (en) 2007-06-12
GT200300149AA (es) 2009-07-09
CN1310643C (zh) 2007-04-18
UA82489C2 (uk) 2008-04-25
JP2005538104A (ja) 2005-12-15
PL375065A1 (en) 2005-11-14
US20090253675A1 (en) 2009-10-08
US20040126423A1 (en) 2004-07-01
GEP20084443B (en) 2008-08-10
US20070160666A1 (en) 2007-07-12
NZ537611A (en) 2007-04-27
AR040588A1 (es) 2005-04-13
PE20050128A1 (es) 2005-03-22
ATE393628T1 (de) 2008-05-15
ECSP085573A (es) 2008-03-26
RS50419B (sr) 2009-12-31
NO20082156L (no) 2005-04-25
AU2003261217A1 (en) 2004-02-16
KR20050045993A (ko) 2005-05-17
JP2008291034A (ja) 2008-12-04
ME00008B (me) 2010-02-10
RS20050061A (en) 2007-09-21
CN101069684A (zh) 2007-11-14
AU2003261217B2 (en) 2009-06-04
EP1992343A1 (en) 2008-11-19
PT1531805E (pt) 2008-06-19
ME00207B (me) 2011-02-10
EP1531805A1 (en) 2005-05-25
PA8577901A1 (es) 2004-10-08
EP1531805B1 (en) 2008-04-30
HRP20050081A2 (en) 2005-08-31
TNSN05022A1 (en) 2007-05-14
HK1080384A1 (en) 2006-04-28
SI1531805T1 (sl) 2008-08-31
US20080275020A1 (en) 2008-11-06
ZA200500196B (en) 2006-07-26
IL191348A0 (en) 2008-11-03
MA27289A1 (fr) 2005-04-01
RS20080072A (en) 2008-11-28
CR9767A (es) 2008-04-10
BR0312933A (pt) 2005-07-12
AU2009200768A1 (en) 2009-03-19
ECSP055573A (es) 2005-04-18
EA008888B1 (ru) 2007-08-31
MEP30808A (en) 2010-10-10
AR067030A2 (es) 2009-09-30
IL166279A0 (en) 2006-01-15
ES2303603T3 (es) 2008-08-16
MXPA05001004A (es) 2005-05-16
HRP20080518A2 (en) 2009-03-31
KR20080070089A (ko) 2008-07-29
EA200500279A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
IS7637A (is) Samsetning sem samanstendur af kólestról upptöku hindra, HMG-COA redúktasa hindra og bindiefni
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
AU2003262747A8 (en) Compounds, compositions, and methods
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
HK1070656A1 (en) Compounds, compositions, and methods
EP1812049A4 (en) KALLIKREIN INHIBITORS AND USES THEREOF
EP1542699A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
IL226339B (en) Aptamers that bind to 5c, preparations containing them and their uses
AU2003270015A8 (en) Compounds, compositions, and methods
ZA200606176B (en) Novel Hydroxy-6-heteroarylphenanthridines and their as PDE4 inhibitors
AU2003299612A8 (en) Compounds, compositions and methods
EP1684754A4 (en) HMG COA REDUCTASE INHIBITORS AND METHOD
IL167936A0 (en) Compounds, compositions,and methods
EP1633311A4 (en) COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTATHION REDUCTASE
PL374833A1 (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU2003277079A8 (en) Compounds, compositions, and methods
DK1778265T3 (da) Guanylhydrazoneforbindelser, sammensætninger, fremgangsmåder og anvendelse
GB0216154D0 (en) Metal chelates
EP1558589A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1554265A4 (en) COMPOSITIONS, COMPOSITIONS AND M THODES
GB0417036D0 (en) Compounds, compositions and devices